On September 11, ASCENTAGE fell 5.21% in regular trading, trading at HK$31.04/share, with turnover of HK$48.95 million. The stock has declined for two consecutive trading days and is approaching its 52-week low of HK$30.00.

Multiple factors are weighing on sentiment. The broader biotechnology sector remains under sustained pressure, with peers declining broadly: METIS TECHBIO-P down 12.93%, AKESO down 3.47%, INNOVENT BIO down 2.28%, BEONE MEDICINES down 1.35%, and KEYMED BIO-B down 0.75%.

On the fundamental side, the company's interim results disclosed in August showed first-half revenue of RMB 302.2 million, up 29% year-over-year, driven by a 33% increase in product sales to RMB 282.4 million from its two commercialized oncology drugs. However, net loss widened significantly from RMB 591 million to RMB 817 million year-over-year, reflecting rising expenses. Additionally, the company's up-to-US$200 million ATM offering plan launched in July to fund global R&D and commercialization continues to weigh on market sentiment due to potential dilution concerns.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)